Logo image of GBT

GLOBAL BLOOD THERAPEUTICS IN (GBT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:GBT - US37890U1088 - Common Stock

68.49 USD
+0.01 (+0.01%)
Last: 10/4/2022, 8:00:01 PM
68.49 USD
0 (0%)
After Hours: 10/4/2022, 8:00:01 PM
Fundamental Rating

2

Taking everything into account, GBT scores 2 out of 10 in our fundamental rating. GBT was compared to 530 industry peers in the Biotechnology industry. GBT may be in some trouble as it scores bad on both profitability and health. GBT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year GBT has reported negative net income.
GBT Yearly Net Income VS EBIT VS OCF VS FCFGBT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 -100M -200M -300M

1.2 Ratios

Industry RankSector Rank
ROA -37.05%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GBT Yearly ROA, ROE, ROICGBT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 -50 -100 -150

1.3 Margins

Industry RankSector Rank
OM -127.41%
PM (TTM) -137.3%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GBT Yearly Profit, Operating, Gross MarginsGBT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 0 -2K -4K -6K -8K -10K

More info and screens

2

2. Health

2.1 Basic Checks

GBT does not have a ROIC to compare to the WACC, probably because it is not profitable.
GBT has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, GBT has a worse debt to assets ratio.
GBT Yearly Shares OutstandingGBT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 20M 40M 60M
GBT Yearly Total Debt VS Total AssetsGBT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of 1.24, we must say that GBT is in the distress zone and has some risk of bankruptcy.
A Debt/Equity ratio of 4.92 is on the high side and indicates that GBT has dependencies on debt financing.
Industry RankSector Rank
Debt/Equity 4.92
Debt/FCF N/A
Altman-Z 1.24
ROIC/WACCN/A
WACC10.15%
GBT Yearly LT Debt VS Equity VS FCFGBT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 200M -200M 400M

2.3 Liquidity

GBT has a Current Ratio of 6.88. This indicates that GBT is financially healthy and has no problem in meeting its short term obligations.
GBT has a Quick Ratio of 6.17. This indicates that GBT is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 6.88
Quick Ratio 6.17
GBT Yearly Current Assets VS Current LiabilitesGBT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 200M 400M 600M 800M

More info and screens

4

3. Growth

3.1 Past

GBT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.51%.
Looking at the last year, GBT shows a very strong growth in Revenue. The Revenue has grown by 42.53%.
EPS 1Y (TTM)-16.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.5%
Revenue 1Y (TTM)42.53%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%50.46%

3.2 Future

The Earnings Per Share is expected to grow by 9.02% on average over the next years. This is quite good.
Based on estimates for the next years, GBT will show a very strong growth in Revenue. The Revenue will grow by 48.11% on average per year.
EPS Next Y2.94%
EPS Next 2Y18.02%
EPS Next 3Y21.63%
EPS Next 5Y9.02%
Revenue Next Year47.16%
Revenue Next 2Y50.99%
Revenue Next 3Y48.16%
Revenue Next 5Y48.11%

3.3 Evolution

GBT Yearly Revenue VS EstimatesGBT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 200M 400M 600M 800M 1B
GBT Yearly EPS VS EstimatesGBT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

GBT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GBT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GBT Price Earnings VS Forward Price EarningsGBT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -15.98
GBT Per share dataGBT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as GBT's earnings are expected to grow with 21.63% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.02%
EPS Next 3Y21.63%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GBT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GLOBAL BLOOD THERAPEUTICS IN

NASDAQ:GBT (10/4/2022, 8:00:01 PM)

After market: 68.49 0 (0%)

68.49

+0.01 (+0.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2022-08-08/bmo
Earnings (Next)11-03 2022-11-03/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners0.93%
Ins Owner Change0%
Market Cap4.62B
Revenue(TTM)234.86M
Net Income(TTM)-322.46M
Analysts68.18
Price Target67.97 (-0.76%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 19.68
P/FCF N/A
P/OCF N/A
P/B 39.05
P/tB N/A
EV/EBITDA -15.98
EPS(TTM)-5.01
EYN/A
EPS(NY)-2.93
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS3.48
BVpS1.75
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -37.05%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -127.41%
PM (TTM) -137.3%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 4.92
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.88
Quick Ratio 6.17
Altman-Z 1.24
F-Score3
WACC10.15%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.5%
EPS Next Y2.94%
EPS Next 2Y18.02%
EPS Next 3Y21.63%
EPS Next 5Y9.02%
Revenue 1Y (TTM)42.53%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%50.46%
Revenue Next Year47.16%
Revenue Next 2Y50.99%
Revenue Next 3Y48.16%
Revenue Next 5Y48.11%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

GLOBAL BLOOD THERAPEUTICS IN / GBT FAQ

What is the fundamental rating for GBT stock?

ChartMill assigns a fundamental rating of 3 / 10 to GBT.


What is the valuation status of GLOBAL BLOOD THERAPEUTICS IN (GBT) stock?

ChartMill assigns a valuation rating of 0 / 10 to GLOBAL BLOOD THERAPEUTICS IN (GBT). This can be considered as Overvalued.


How profitable is GLOBAL BLOOD THERAPEUTICS IN (GBT) stock?

GLOBAL BLOOD THERAPEUTICS IN (GBT) has a profitability rating of 3 / 10.


What is the financial health of GLOBAL BLOOD THERAPEUTICS IN (GBT) stock?

The financial health rating of GLOBAL BLOOD THERAPEUTICS IN (GBT) is 4 / 10.